Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23409
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorCappelleri, J. C.en
dc.contributor.authorSacks, H. S.en
dc.contributor.authorLau, J.en
dc.date.accessioned2015-11-24T19:32:24Z-
dc.date.available2015-11-24T19:32:24Z-
dc.identifier.issn0197-2456-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23409-
dc.rightsDefault Licence-
dc.subjectAnti-HIV Agents/adverse effects/*therapeutic useen
dc.subjectBias (Epidemiology)en
dc.subjectData Collection/statistics & numerical dataen
dc.subjectHIV Infections/*drug therapy/mortalityen
dc.subjectHumansen
dc.subjectPublication Biasen
dc.subjectRandomized Controlled Trials as Topic/*statistics & numerical dataen
dc.subjectResearch Designen
dc.subjectSurvival Analysisen
dc.subjectTreatment Outcomeen
dc.titleThe relationship between study design, results, and reporting of randomized clinical trials of HIV infectionen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9315426-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1997-
heal.abstractWe examined whether the study design of randomized clinical trials for medications against human immunodeficiency virus (HIV) may affect the results and whether the outcomes of these trials affect reporting and publication. We used a database of 71 published randomized HIV-related drug efficacy trials and considered the following study design factors: endpoint definition and method of analysis, masked design, sample size, and duration of follow-up. Large variation was noted in the methods of analysis for surrogate endpoints. Often statistical significance for a surrogate endpoint was not associated with statistical significance for the clinical endpoint or for survival in the same trial, although disagreements in the direction of the treatment effect for surrogate endpoints and survival within individual trials were uncommon. Open-label design seemed to affect the magnitude of the treatment effect for two treatments. The magnitude of the treatment effect in trials of zidovudine monotherapy was inversely related to their sample size, but this probably reflected the confounding effect of longer duration of follow-up in large trials (with a resulting loss of efficacy) rather than publication bias. There was, however, evidence for potential bias in reporting and publication of HIV-related trials. Meta-analyses of published trials for specific treatments demonstrated a sizable treatment benefit for all the examined medications regardless of whether these medications were officially approved, controversial, or abandoned, raising concerns about either publication bias or unjustifiable rejection of potentially useful medications. Compared with trials published in specialized journals, trials published in journals of wide readership were larger (p = 0.001) and 4.4 times more likely to report "positive" results (p = 0.01). We identified several examples of trials with "negative" results that have remained unpublished for a long time. In conclusion, study design factors may have an impact on the magnitude and significance of the treatment effect in HIV-related trials. Bias in reporting can further affect the information that these studies provide.en
heal.journalNameControl Clin Trialsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons